Navigation Links
Lilly Provides Update on 2011 Financial Guidance Due to Xigris Withdrawal
Date:10/25/2011

INDIANAPOLIS, Oct. 25, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has updated its full-year 2011 financial guidance as a result of the announced withdrawal of the company's Xigris® product.

Lilly expects to incur a charge in the fourth quarter of 2011 for asset impairments and contractual commitments related to Xigris. The exact amount of the charge has not yet been determined, but is estimated to be in the range of $75.0 million to $95.0 million (pre-tax), or approximately $.05 per share (after tax).

Lilly's full-year 2011 earnings per share guidance on a non-GAAP basis remains unchanged at $4.30 to $4.35. On a reported basis, including the Xigris asset impairment charge, Lilly now expects its full-year 2011 earnings per share to be in the range of $3.84 to $3.89. See the reconciliation below for further detail.

2011 Earnings Per Share Expectations:2011 Expectations2010

Results% GrowthEarnings per share (reported)$3.84 to $3.89$4.58(15)% to (16)%In-process research and development charges associated with
Boehringer Ingelheim collaboration (2011) and Acrux
licensing agreement (2010).23.03Asset impairments and restructuring charges:

Year-to-date charges

Estimated Xigris charge.18

.05.13

-Earnings per share (non-GAAP)$4.30 to $4.35$4.74(8)% to (9)%About Eli Lilly and CompanyLilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  C-LLY

This press release contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. There are significant risks and uncertainties in pharmaceutical research and development. There can be no guarantees with respect to pipeline products that the products will receive the necessary clinical and manufacturing regulatory approvals or that they will prove to be commercially successful. Pharmaceutical products can develop unexpected safety or efficacy concerns. The company's results may also be affected by such factors as competitive developments affecting current products; market uptake of recently-launched products; the timing of anticipated regulatory approvals and launches of new products; regulatory actions regarding currently marketed products; issues with product supply; regulatory changes or other developments; regulatory compliance problems or government investigations; patent disputes; changes in patent law or regulations related to data-package exclusivity; other litigation involving current or future products; the impact of governmental actions regarding pricing, importation, and reimbursement for pharmaceuticals, including U.S. health care reform; changes in tax law; asset impairments and restructuring charges; acquisitions and business development transactions; and the impact of exchange rates and global macroeconomic conditions. For additional information about the factors that affect the company's business, please see the company's latest Form 10-Q and Form 10-K filed with the U.S. Securities and Exchange Commission. The company undertakes no duty to update forward-looking statements.

Xigris® (drotrecogin alfa (activated)), Lilly

(Logo:  http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016  Hologic, Inc. (Nasdaq: HOLX ... the fiscal second quarter ended March 26, 2016.  ... increased 41.2%, and non-GAAP diluted EPS of $0.47 ... on a reported basis, and 6.3% on a ... another good quarter, highlighted by 14.6% growth in ...
(Date:4/27/2016)... Transparency Market Research has published ... Global Industry Analysis, Size, Share, Growth, Trends, and Forecast ... skincare devices market was valued at US$ 7,255.8 Mn ... CAGR of 10.1% from 2015 to 2023 to reach ... full Skincare Devices Market (Treatment Device - LED Therapy Devices, ...
(Date:4/27/2016)... April 27, 2016 ... the  "Global Anesthesia Disposables Market 2016-2020"  report ... ) ,The global anesthesia disposables market ... of 4.03% during the period 2016-2020.  ... threat to patients, safety. Organizations like the ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip meals occasionally ... miss. That was among the many new lifestyle diet tips offered by nutritionists Pam ... Hour® Power of Water® radio show. Bonny and Lawrence noted that because proper nutrition, ...
(Date:4/29/2016)... ... ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of 100 on Tampa ... for Tampa’s Best Places to Work. They were ranked in the Big Category, which ... our team,” says RMS Human Resources Manager Irene Miller. “We work hard to build ...
(Date:4/29/2016)... ... 2016 , ... Nike Softball Camp at the College of Brockport in New ... girls aged 10-18. All facets of the game will be covered; hitting, fielding, base-running, ... one of the finest softball facilities in the region. The outstanding professional college staff ...
(Date:4/29/2016)... ... April 29, 2016 , ... HEALTHCAREfirst , ... coding services, and Deyta Analytics, recently announced the recipients of the fourth annual ... quality as measured from the caregiver’s point of view. The official list of ...
(Date:4/29/2016)... ... 2016 , ... Intellitec Solutions will be a sponsor at ... the Broward County Convention Center. The event is a chance for finance professionals ... public facility management. Intellitec Solutions will highlight their customized accounting solutions designed for ...
Breaking Medicine News(10 mins):